Boston, MA -- (SBWIRE) -- 09/16/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Simmons First National Corporation (NASDAQ:SFNC), Chimerix Inc (NASDAQ:CMRX), Inovio Pharmaceuticals Inc (NYSEMKT:INO), Rubicon Minerals Corp. (USA)(NYSEAMEX:RBY)
Simmons First National Corporation (NASDAQ:SFNC) shares climbed 5.62% and closed at $28.38. The company on Sept. 12 announced the U.S. Bankruptcy Court approved a Stock Purchase Agreement between SFNC and Rogers Bancshares, Inc. ("RBI") for the stock of Metropolitan National Bank ("MNB"). SFNC will purchase all of the issued and outstanding shares of common stock free and clear of all liens, claims and encumbrances, and assumes no liabilities of RBI. Under the terms of the agreement, RBI will receive $53.6 million in cash. The transaction is expected to close during the fourth quarter of 2013 and is subject to customary regulatory approval.
How Should Investors Trade SFNC After The Recent Volatility? Get Free Report Here
Chimerix Inc (NASDAQ:CMRX) shares climbed 5.49% and closed at $19.42. The company on Sept. 11 said its experimental drug failed to show significant benefit in a mid-stage study involving a type of viral infection that mainly affects the lungs. The drug, brincidofovir, was being tested on 48 patients with blood and bone marrow cancers who had adenovirus infection (AdV), a potentially fatal condition which has no known approved treatments. The trial was designed to evaluate the potential to decrease the viral infection or prevent its progression. The drug was given to patients once or twice a week.
How Should Investors Trade CMRX After The Recent Volatility? Get Free Report Here
Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares increased 5.38% to $2.35. Roche (six:RO)(six:ROG)(otcqx:RHHBY) and Inovio Pharmaceuticals, Inc. on Sept. 10 announced that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated robust T-cell responses in animal models.
Is INO A Good Buy After The Recent Price Movement? Find Out Here
Rubicon Minerals Corp. (USA)(NYSEAMEX:RBY) shares increased 5.26% and close at $1.40. The company, on August 9, announces the filing of a technical report for its F2 Gold System, which comprises part of the Company's flagship Phoenix Gold Project, located in Red Lake, Ontario, in accordance with the requirements of National Instrument 43-101 Standards of Disclosure for Mineral Projects (the "Technical Report"). The Technical Report, dated effective June 25, 2013, was prepared by SRK Consulting (Canada) Inc. and Soutex Inc., both of which are independent of Rubicon.
Is RBY A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)